Literature DB >> 15289310

Autoantibodies to Annexin XI-A and Other Autoantigens in the Diagnosis of Breast Cancer.

Félix Fernández-Madrid1, Naimei Tang, Huda Alansari, José L Granda, Larry Tait, Kathryn C Amirikia, Mihail Moroianu, Xiaoju Wang, Robert L Karvonen.   

Abstract

We report on the identification of autoantigens commonly recognized by sera from patients with breast cancer. We selected ten sera from patients with invasive ductal carcinoma (IDC) of the breast with high titer IgG autoantibodies for biopanning of a T7 phage breast cancer cDNA display library. A high throughput method involved the assembly of 938 T7 phages encoding potential breast cancer autoantigens. Microarrays of positive phages were probed with sera from 90 patients with breast cancer [15 patients with ductal carcinoma in situ (DCIS) and 75 patients with IDC of the breast], with 51 non-cancer control sera and with sera from 21 patients with systemic autoimmune diseases. A 12-phage breast cancer predictor group was constructed with phage inserts recognized by sera from patients with breast cancer and not by non-cancer or autoimmune control sera (P < 0.0001). Several autoantigens including annexin XI-A, the p80 subunit of the Ku antigen, ribosomal protein S6, and other unknown autoantigens could significantly discriminate between breast cancer and non-cancer control sera. Biopanning with three different sera led to the cloning of partial cDNA sequences identical to annexin XI-A. IgG autoantibodies reacting with the amino acid 41-74 sequence of annexin XI-A were found in 19% of all women with breast cancer but in 60% of sera from women with DCIS of the breast. In addition, partial sequences identical to annexin XI-A, nucleolar protein interacting with the forkhead-associated (FHA) domain of pKi-67, the KIAA1671 gene product, ribosomal protein S6, cyclin K, elongation factor-2, Grb2-associated protein 2, and other unknown proteins could distinguish DCIS from IDC of the breast and appear to be potential biomarkers for the diagnosis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289310     DOI: 10.1158/0008-5472.CAN-03-0932

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

Review 1.  Serologic laboratory findings in malignancy.

Authors:  Félix Fernández Madrid; Marie-Claire Maroun
Journal:  Rheum Dis Clin North Am       Date:  2011-11       Impact factor: 2.670

2.  Improving seroreactivity-based detection of glioma.

Authors:  Nicole Ludwig; Andreas Keller; Sabrina Heisel; Petra Leidinger; Veronika Klein; Stefanie Rheinheimer; Claudia U Andres; Bernhard Stephan; Wolf-Ingo Steudel; Norbert M Graf; Bernhard Burgeth; Joachim Weickert; Hans-Peter Lenhof; Eckart Meese
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

3.  Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing.

Authors:  Mei-Chong Wendy Lee; Fernando J Lopez-Diaz; Shahid Yar Khan; Muhammad Akram Tariq; Yelena Dayn; Charles Joseph Vaske; Amie J Radenbaugh; Hyunsung John Kim; Beverly M Emerson; Nader Pourmand
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-22       Impact factor: 11.205

Review 4.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

5.  Latest updates on antiretinal autoantibodies associated with vision loss and breast cancer.

Authors:  Grazyna Adamus
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-03-09       Impact factor: 4.799

6.  Biologic characteristics of premalignant breast disease.

Authors:  Kimberly Cole; Maria Tabernero; Karen S Anderson
Journal:  Cancer Biomark       Date:  2010       Impact factor: 4.388

7.  Spectra of antinuclear antibodies in patients with squamous cell carcinoma of the lung and of the head and neck.

Authors:  Félix Fernández Madrid; Robert L Karvonen; John Ensley; Michael Kraut; José L Granda; Huda Alansari; Naimei Tang; John E Tomkiel
Journal:  Cancer Detect Prev       Date:  2005-01-28

8.  Anti-centrosome antibodies in breast cancer are the expression of autoimmunity.

Authors:  Marie-Claire Maroun; Ofelia Olivero; Leonard Lipovich; Azadeh Stark; Larry Tait; Sudeshna Bandyopadhyay; Matthew Burke; Richard Zarbo; Dhananjay Chitale; S David Nathanson; Mike Long; Carol Peebles; Félix Fernández Madrid
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

9.  Serum GFAP autoantibody as an ELISA-detectable glioma marker.

Authors:  Ping Wei; Wei Zhang; Liu-Song Yang; Hai-Shi Zhang; Xiao-En Xu; Ying-Hua Jiang; Feng-Ping Huang; Qian Shi
Journal:  Tumour Biol       Date:  2013-04-16

Review 10.  Antigen-specific immunotherapy of cervical and ovarian cancer.

Authors:  Chien-Fu Hung; T C Wu; Archana Monie; Richard Roden
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.